Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Biotechnology

Healthcare
$945.53 -0.90%

-$5.45 today

Market cap
$97.80B
Beta
0.24
P/E (TTM)
14.2
EPS (TTM)
$42.53
Dividend yield
0.60%
52W Low $506.38High $821.11

Volume 0.70M

Average 0.91M

REGN Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

Retained Earnings · Q2 FY2026 · quarter ended Jun 2026

Retained earnings rises 11.7% from a year ago

Retained earnings stood at $37.62B at the end of Q2 FY2026, up 11.7% from a year earlier and up 3.3% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.

Context

  • Retained earnings amounted to 90.2% of total assets at the end of Q2 FY2026, up 2.0 pp from a year earlier.
  • Retained earnings increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps rising in the next quarterly balance sheet after a +11.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$37.62B+3.3% QoQ
Last fiscal yearDec 2025
$35.8B+13.0% YoY
Year agoJun 2025
$33.68B+11.7% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.7%——
1 year+13.0%——
3-year CAGR+15.4%——
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
35.8B USD
Year-over-year change
+13.0%
4-year CAGR
+17.2%

Retained Earnings vs competitors

How REGN compares with its peers on the latest reported figures

  • REGN's Jun 2026 retained earnings of $37.62B is the 2nd highest of the 9 companies compared; the peer median is $3.31B.
  • Its year-over-year change of +11.7% is the 4th highest of 9, against a peer median of -0.2%.
  • Retained earnings amounts to 90.2% of total assets for REGN, versus a peer median of 33.9%.
REGN Competitors Peer median
Retained Earnings for REGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVSNovartis AGJun 2026$39.65B -4.5%-11.0%32.5%
REGNRegeneron Pharmaceuticals, Inc.Jun 2026$37.62B +11.7%+15.4%90.2%
BIIBBiogen Inc.Jun 2026$20.97B +4.1%+7.7%65.4%
AZNAstraZeneca PLCSep 2026$14.04B +71.0%—11.7%
GMABGenmab A/SJun 2026$4.42B +22.9%-34.9%35.3%
GILDGilead Sciences, Inc.Jun 2026$2.2B -80.6%-4.3%4.5%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026-$1.19B -29.6%—412.8%
OCULOcular Therapeutix, Inc.Mar 2026-$1.25B -30.4%—170.0%
AMGNAmgen Inc.Jun 2026-$22.28B +13.4%—23.3%
Peer median (excluding REGN) $3.31B-0.2%-7.7%33.9%

Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.89B3.11B2.73B2.49B3.12B
Short-term Investments2.81B4.64B8.11B6.52B5.49B
Net Receivables6.04B5.33B5.67B6.21B5.74B
Inventory1.95B2.4B2.58B3.09B3.2B
Other Current Assets00386.6M349.2M474.8M
Total Current Assets14.01B15.88B19.48B18.66B18.02B
Property, Plant & Equipment (Net)3.48B3.76B4.15B4.6B5.12B
Goodwill00000
Intangible Assets6.7M915.5M1.04B1.15B1.26B
Long-term Investments6.84B6.59B5.4B8.9B10.26B
Tax Assets876.9M1.72B2.58B3.31B4.08B
Other Non-current Assets216.1M336.4M444.1M1.14B1.82B
Total Non-current Assets11.42B13.33B13.6B19.1B22.54B
Total Assets25.43B29.21B33.08B37.76B40.56B
Account Payables564M589.2M606.6M789.5M939M
Short-term Debt00000
Tax Payables326.3M300K0213.2M0
Deferred Revenue442M477.9M458.9M627.7M553M
Other Current Liabilities00000
Total Current Liabilities3.93B3.14B3.42B3.94B4.37B
Long-term Debt1.98B1.98B1.98B1.98B1.99B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)73.3M69.8M126.7M185.7M208.7M
Other Non-current Liabilities680.2M638M854.1M1.57B2.02B
Total Non-current Liabilities2.73B3.41B3.68B4.46B4.93B
Total Liabilities6.67B6.55B7.11B8.41B9.3B
Common Stock100K100K100K100K100K
Retained Earnings18.97B23.31B27.26B31.67B35.8B
Accumulated OCI(26.2M)(238.8M)(80.9M)(7.9M)77.5M
Other Stockholders Equity00000
Minority Interest00000
Total Equity18.77B22.66B25.97B29.35B31.26B
Total Debt2.7B2.7B2.7B2.7B2.71B
Net Debt(185.9M)(404.5M)(27.1M)216.2M(412.2M)

Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Intrinsic Alpha fair value

Locked

Current Price

$945.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.